Zilico, which is part of the Deepbridge Life Sciences EIS portfolio, has announced that Bradford Teaching Hospitals NHS Foundation Trust has received funding from the Michelle Henderson Cervical Cancer Trust, allowing them to introduce ZedScan™ to aim to further improve the diagnosis of cervical cancer in women referred to its colposcopy clinics at Bradford Royal Infirmary.

Zilico, which is part of the Deepbridge Life Sciences EIS portfolio, has announced that Bradford Teaching Hospitals NHS Foundation Trust has received funding from the Michelle Henderson Cervical Cancer Trust.

ZedScan, the flagship product of Zilico, examines the electrical resistance properties of human tissues, through the measurement and interpretation of electrical resistance of that tissue and then provides an objective method to differentiate between normal, pre-cancerous, and cancerous cells.

You can read more about this funding here:https://zilico.co.uk/news-and-events/news/bradford-teaching-hospitals-nhs-foundation-trust-adopts-zedscan.html 

By following this link, you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites.  

To find out more about Zilico please click here.